Regen BioPharma Inc (RGBP)

[Mutat]

WHERE IN THE OTC ARE YOU GOING TO FIND A CEO THAT HAS PUT OUT 16 8K'S WITH NO SALARY AND HASN'T SAID A WORD. TOTAL SILENCE NO ATTEMPT TO BLOW SMOKE OR PUMP STOCK. MY BET IS A BUYOUT.


On July 13 RGBP filed an 8k listing the Company’s issued patents and pending patents:
1. GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS): Patent No: 8263571
2. METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION: PatentNo :11,053,503 
3. METHODS OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND: Patent No: 10,088,485
4. MODULATION OF NR2F6 AND METHODS AND USES THEREOF: Patent No: 9091696
IP for which a Notice of Allowance has been granted. A Notice of Allowance is notification by the USPTO to the applicant that the USPTO intends to issue a patent 
5. ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES: Application Number: 15/162,370
IP for which Patent Protection has expired due to non payment of fees for which revival is in process: 
6. METHOD OF CANCER TREATMENT USING SIRNA SILENCING Patent No: 8389708
IP for which a Notice of Allowance was granted but classified as abandoned by the USPTO. Revival in progress. 
7. UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS: Application Number: 15/494,358
Active Patent Applications: 
8. ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL; Application Number 17035955.
9. REDUCTION OF POST-SURGERY CANCER METASTASIS BY COMBINATION OF CANNABIDIOL AND NR2F6 INHIBITION. Application Number 17037284
10. SUPPRESSION OF PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF NR2F6 Application Number 17087386
11. STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY Application Number 17010720
12. SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN HUMANS Application Number 15820324
13. SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY. Application Number 15364111
Patent issued to Zander Therapeutics, Inc. derived from intellectual property licensed by Zander Therapeutics Inc. from KCL. 
14. CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES: Patent Number: 10,030,227